Study Title
ANBL1821: A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma
Protocol ID
ANBL1821
Condition/s
Solid tumours (Neuroblastoma)
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA, SA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Sites
Perth Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Women's & Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Royal Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year and older
International registry ID's
NCT03794349
| Study Title | ANBL1821: A Phase 2 Randomised Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# TBD) in Children with Relapsed& Refractory or Progressive Neuroblastoma |
|---|---|
| Protocol ID | ANBL1821 |
| Disease (Sub Disease) | Solid tumours (Neuroblastoma) |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / QLD / VIC / WA / SA / NZ |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03794349 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 28/05/2019 |
| Sites | Perth Children's Hospital / Queensland Children's Hospital / The Children's Hospital at Westmead/ Sydney Children's Hospital / Royal Children's Hospital / Christchurch Hospital / Starship Hospital / John Hunter Children's Hospital/ Women's & Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year and older |
| International registry ID's | NCT03794349 |